according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

#### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Milbemycin Oxime / Lufenuron Formulation

Manufacturer or supplier's details

Company : MSD

Address : No. 485 Jing Tai Road

Pu Tuo District - Shanghai - China 200331

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

#### 2. HAZARDS IDENTIFICATION

### **Emergency Overview**

Appearance : solid
Colour : brown
Odour : odourless

May cause an allergic skin reaction. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

**GHS Classification** 

Skin sensitisation : Category 1

Reproductive toxicity : Category 1B

Specific target organ toxicity - :

repeated exposure

Category 1

Category 1

Short-term (acute) aquatic

:

hazard

Long-term (chronic) aquatic

: Category 1

hazard

## **GHS** label elements

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Hazard pictograms :







Signal word : Danger

Hazard statements : H317 May cause an allergic skin reaction.

H360D May damage the unborn child.

H372 Causes damage to organs through prolonged or repeated

exposure.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements

#### Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing should not be allowed out of

the workplace.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

## Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P333 + P313 If skin irritation or rash occurs: Get medical ad-

vice/ attention.

P362 + P364 Take off contaminated clothing and wash it before

reuse.

P391 Collect spillage.

### Storage:

P405 Store locked up.

## Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

#### Physical and chemical hazards

Not classified based on available information.

### **Health hazards**

May cause an allergic skin reaction. May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

#### **Environmental hazards**

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

#### Other hazards which do not result in classification

None known.

#### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Lufenuron (ISO)	103055-07-8	>= 30 -< 50
Cellulose	9004-34-6	>= 10 -< 20
Starch	9005-25-8	>= 1 -< 10
Milbemycin Oxime	129496-10-2	>= 1 -< 2.5

#### 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water. May cause an allergic skin reaction.

Most important symptoms and effects, both acute and

May damage the unborn child.

delayed

Causes damage to organs through prolonged or repeated

exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

## 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing : None known.

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

media

Specific hazards during fire-

fiahtina

ucts

Hazardous combustion prod: : Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

Exposure to combustion products may be a hazard to health.

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

#### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

**Environmental precautions** Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for

containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

## 7. HANDLING AND STORAGE

Handling

Technical measures See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling Do not get on skin or clothing.

Do not breathe dust, fume, gas, mist, vapours or spray.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

practice, based on the results of the workplace exposure as-

sessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

**Storage** 

Conditions for safe storage : Keep in properly labelled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

#### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Lufenuron (ISO)	103055-07-8	TWA	OEB 3 (>= 10 < 100 μg/m3)	Internal
Cellulose	9004-34-6	PC-TWA	10 mg/m3	CN OEL
		TWA	10 mg/m3	ACGIH
Starch	9005-25-8	TWA	10 mg/m3	ACGIH
Milbemycin Oxime	129496-10-2	TWA	0.1 mg/m3 (OEB2)	Internal

**Engineering measures** : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con-

tainment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

#### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : solid

Colour : brown

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Flammability (liquids) : Not applicable

Upper explosion limit / Upper : No data available

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2023/09/30 6365217-00008 Date of first issue: 2020/09/21 2.6

flammability limit

Lower explosion limit / Lower :

flammability limit

No data available

Vapour pressure Not applicable

Relative vapour density Not applicable

Relative density No data available

No data available Density

Solubility(ies)

Water solubility soluble

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature No data available

Decomposition temperature No data available

Viscosity

Viscosity, kinematic Not applicable

Explosive properties Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Molecular weight No data available

Particle size No data available

#### 10. STABILITY AND REACTIVITY

Reactivity Not classified as a reactivity hazard. Chemical stability Stable under normal conditions.

tions

Possibility of hazardous reac- : Can react with strong oxidizing agents.

: None known. Conditions to avoid Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

### 11. TOXICOLOGICAL INFORMATION

Exposure routes Skin contact

> Ingestion Eye contact

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

**Acute toxicity** 

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Acute inhalation toxicity : Acute toxicity estimate: > 10 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist Method: Calculation method

Acute dermal toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

**Components:** 

Lufenuron (ISO):

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): 2,350 mg/m3

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Milbemycin Oxime:

Acute oral toxicity : LD50 (Rat): 532 - 863 mg/kg

LD50 (Mouse): 722 - 946 mg/kg

Acute inhalation toxicity : LC50 (Rat): 1,200 mg/m3

Exposure time: 4 h

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

## **Components:**

### Lufenuron (ISO):

Species : Rabbit
Method : Draize Test
Result : No skin irritation

### Milbemycin Oxime:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

## Serious eye damage/eye irritation

Not classified based on available information.

### **Components:**

### Lufenuron (ISO):

Species : Rabbit

Result : No eye irritation Method : Draize Test

Starch:

Species : Rabbit

Result : No eye irritation

Milbemycin Oxime:

Species : Rabbit

Result : No eye irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

May cause an allergic skin reaction.

### Respiratory sensitisation

Not classified based on available information.

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

## **Components:**

Lufenuron (ISO):

Test Type : Maximisation Test

Species : Guinea pig

Assessment : May cause sensitisation by skin contact.

Result : Sensitiser

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Milbemycin Oxime:

Exposure routes : Skin contact
Species : Guinea pig
Result : negative

#### Germ cell mutagenicity

Not classified based on available information.

## **Components:**

Lufenuron (ISO):

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Mouse Lymphoma Test system: Chinese hamster cells

Result: negative

Test Type: Cytogenetic assay

Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: rat hepatocytes

Result: negative

Test system: Human lymphocytes

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Result: negative

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Test Type: Unscheduled DNA synthesis test (UDS) in testicu-

lar cells Species: Rat Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Milbemycin Oxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Lufenuron (ISO):

Species : Rat
Application Route : Ingestion
Exposure time : 18 month(s)
Result : negative

Carcinogenicity - Assess- : Weight of evidence does not support classification as a car-

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

ment cinogen

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

May damage the unborn child.

**Components:** 

Lufenuron (ISO):

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity - Parent: NOAEL: 8.3 mg/kg wet weight Early Embryonic Development: NOAEL: 20.9 mg/kg body

weight

Result: Animal testing did not show any effects on fertility.

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

General Toxicity Maternal: NOAEL: 500 mg/kg body weight Developmental Toxicity: NOAEL: 1,000 mg/kg body weight

Symptoms: No adverse effects

Remarks: No significant adverse effects were reported

Test Type: Fertility/early embryonic development

Species: Rat

**Application Route: Ingestion** 

General Toxicity Maternal: NOAEL: 20.9 mg/kg body weight

Embryo-foetal toxicity: 8.3 mg/kg body weight

Result: foetal abnormalities

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on

animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Milbemycin Oxime:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Dog

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Ingestion

Result: negative

Test Type: Embryo-foetal development

Species: Dog

Application Route: Ingestion

Result: negative

### STOT - single exposure

Not classified based on available information.

### **Components:**

Lufenuron (ISO):

Assessment : The substance or mixture is not classified as specific target

organ toxicant, single exposure.

#### STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

### **Components:**

Lufenuron (ISO):

Exposure routes : Oral

Target Organs : Central nervous system, Lungs, Liver, Stomach

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

Milbemycin Oxime:

Exposure routes : Ingestion

Target Organs : Central nervous system

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

#### Repeated dose toxicity

# **Components:**

## Lufenuron (ISO):

Species : Rat
NOAEL : 5.34 mg/kg
Application Route : oral (feed)
Exposure time : 4 Months

Target Organs : Central nervous system, digestive system

Symptoms : central nervous system effects

Species : Rat

NOAEL : 1.93 mg/kg Application Route : oral (feed) Exposure time : 2 yr

Symptoms : central nervous system effects, Convulsions

Species : Mouse
NOAEL : 2.12 mg/kg
Application Route : oral (feed)
Exposure time : 18 Months

Target Organs : Central nervous system, Liver, Prostate Symptoms : central nervous system effects, Convulsions

Species : Dog
NOAEL : 7.02 mg/kg
Application Route : oral (feed)
Exposure time : 1 yr

Target Organs : Central nervous system, Liver, Lungs Symptoms : Convulsions, Fatality, Irregularities

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Milbemycin Oxime:

Species : Rat

NOAEL : 3 mg/kg

LOAEL : 15 mg/kg

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Application Route : Ingestion Exposure time : 90 Days

Symptoms : Liver disorders, Blood disorders

Species : Dog
LOAEL : 8.6 mg/kg
Application Route : Ingestion
Exposure time : 3 Days
Symptoms : Tremors

**Aspiration toxicity** 

Not classified based on available information.

**Experience with human exposure** 

**Components:** 

Lufenuron (ISO):

General Information : Remarks: May be harmful if swallowed.

May cause neurotoxic effects.

Milbemycin Oxime:

Ingestion : Symptoms: Salivation, Convulsions, Diarrhoea, Weakness,

Vomiting, Tremors, Coma

Remarks: Based on Animal Evidence

12. ECOLOGICAL INFORMATION

**Ecotoxicity** 

**Components:** 

Lufenuron (ISO):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 73,100 μg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): > 29,000 μg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 370 μg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Americamysis): 0.042 µg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic

plants

EC50 (Raphidocelis subcapitata (freshwater green alga)): 209

μg/l

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Exposure time: 72 h

Method: OECD Test Guideline 201

EC50 (Scenedesmus subspicatus): 17 μg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

Toxicity to fish (Chronic tox-

icity)

10,000

NOEC (Oncorhynchus mykiss (rainbow trout)): 80 μg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

NOEC (Oncorhynchus mykiss (rainbow trout)): 20 µg/l

Exposure time: 359 d

Method: OECD Test Guideline 229

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 8.38 µg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

NOEC (Daphnia magna (Water flea)): 90 μg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

NOEC (Chironomus riparius (harlequin fly)): 2 µg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

10

Cellulose:

LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Toxicity to fish

Exposure time: 48 h

Remarks: Based on data from similar materials

Milbemycin Oxime:

LC50 (Oncorhynchus mykiss (rainbow trout)): 0.16 µg/l Toxicity to fish

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.03 μg/l

Toxicity to algae/aquatic

plants

Exposure time: 48 h

EC50:  $> 87 \mu g/l$ Exposure time: 72 h

M-Factor (Acute aquatic tox- :

10.000

Toxicity to daphnia and other : aquatic invertebrates (Chron-

NOEC (Daphnia magna (Water flea)): 0.01 µg/l

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2023/09/30 6365217-00008 Date of first issue: 2020/09/21 2.6

ic toxicity)

M-Factor (Chronic aquatic

toxicity)

10,000

Persistence and degradability

**Components:** 

Cellulose:

Biodegradability Result: Readily biodegradable.

Bioaccumulative potential

**Components:** 

Lufenuron (ISO):

Bioaccumulation Species: Lepomis macrochirus (Bluegill sunfish)

> Bioconcentration factor (BCF): 28 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 5.12

Milbemycin Oxime:

Bioaccumulation Bioconcentration factor (BCF): 440

Partition coefficient: n-

octanol/water

log Pow: 7

Mobility in soil

**Components:** 

Lufenuron (ISO):

Distribution among environ:

mental compartments

log Koc: 5.38

Method: OECD Test Guideline 106

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

**Disposal methods** 

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Empty containers should be taken to an approved waste han-Contaminated packaging

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

#### 14. TRANSPORT INFORMATION

#### International Regulations

**UNRTDG** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Milbemycin Oxime, Lufenuron (ISO))

Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

**IATA-DGR** 

UN/ID No. : UN 3077

Proper shipping name : Environmentally hazardous substance, solid, n.o.s.

(Milbemycin Oxime, Lufenuron (ISO))

Class : 9 Packing group : III

Labels : Miscellaneous

Packing instruction (cargo : 956

aircraft)

Packing instruction (passen: 956

ger aircraft)

Environmentally hazardous : yes

**IMDG-Code** 

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Milbemycin Oxime, Lufenuron (ISO))

Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

**National Regulations** 

GB 6944/12268

UN number : UN 3077

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Milbemycin Oxime, Lufenuron (ISO))

Class : 9
Packing group : III
Labels : 9
Marine pollutant : no

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

#### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

#### 15. REGULATORY INFORMATION

#### **National regulatory information**

Law on the Prevention and Control of Occupational Diseases

### **Yangtze River Protection Law**

This product does not contain any dangerous chemicals prohibited for inland river transport.

#### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### **16. OTHER INFORMATION**

Revision Date : 2023/09/30

**Further information** 

Sources of key data used to compile the Safety Data

complie the Salety Data

Sheet

: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CN OEL : Occupational exposure limits for hazardous agents in the

workplace - Chemical hazardous agents.

ACGIH / TWA : 8-hour, time-weighted average

CN OEL / PC-TWA : Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and

according to GB/T 16483 and GB/T 17519



# Milbemycin Oxime / Lufenuron Formulation

Version Revision Date: SDS Number: Date of last issue: 2023/04/04 2.6 2023/09/30 6365217-00008 Date of first issue: 2020/09/21

Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods: vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### **Disclaimer**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN